Management Projects 2026 Revenue of Approximately $600M
Management projects 2026 revenue of approximately $600M-$610M, reflecting growth of approximately 12% to 14% over full year 2025. Management also projects full year positive adjusted EBITDA of approximately $80M-$82M in 2026 and anticipates full year net income in 2026. Additionally, management expects continued positive cash flow for 2026.
Trade with 70% Backtested Accuracy
Analyst Views on ATRC
About ATRC
About the author
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
DexCom Reports Q4 2025 Revenue of $1.26 Billion, Up 13%
- Revenue Growth: DexCom's preliminary Q4 2025 total revenue reached approximately $1.26 billion, reflecting a 13% year-over-year increase and surpassing the Zacks consensus estimate of $1.25 billion, indicating strong market performance.
- U.S. and International Performance: U.S. revenues were about $892 million, an 11% increase year-over-year, while international revenues rose 18% to around $368 million, demonstrating the effectiveness of the company's global expansion strategy.
- Gross and Operating Margins: The company estimates an adjusted gross profit margin of approximately 61% and an operating margin of 20-21% for 2025, with elevated manufacturing scrap rates impacting margins, yet operational leverage has helped achieve overall margin expansion.
- 2026 Outlook: DexCom projects total revenues for 2026 to be between $5.16 billion and $5.25 billion, representing an estimated growth of 11-13%, with expected gross margins improving to 63-64%, reflecting strong confidence in future growth and robust market demand.
VentriPoint Diagnostics Secures $1 Million Funding to Propel AI Medical Imaging Growth
- Market Growth Potential: The AI medical imaging market is projected to grow at an annual rate of 25.8% through 2034, driving a shift in healthcare from traditional hardware to agile, software-defined intelligence, creating significant opportunities for companies like VentriPoint.
- Successful Funding: VentriPoint doubled its private placement from $500,000 to $1 million, with proceeds earmarked for critical commercialization activities and manufacturing scale-up, ensuring the company maintains a competitive edge in the rapidly evolving market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby enhancing market competitiveness and driving customer adoption.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, bringing over 15 years of management experience in the medical technology sector, which is viewed as a key step in executing strategies to drive market adoption and revenue growth.
AtriCure Inc (ATRC) Releases 2025 Product Pipeline Analysis Report
- Product Pipeline Overview: AtriCure Inc's newly released 2025 Product Pipeline Analysis report provides key insights into its major products and brands, enhancing decision-making capabilities in the competitive medical technology market.
- Technical Expertise: AtriCure specializes in developing and providing medical devices for cardiac surgeries, including the Isolator Synergy ablation system and AtriClip left atrial appendage exclusion system, addressing the needs of electrophysiologists and cardiothoracic surgeons.
- Market Coverage: The company operates in multiple countries including the US, Germany, France, the UK, Canada, and Australia, showcasing its extensive global footprint aimed at enhancing competitiveness in the cardiac medical device sector.
- Brand Diversity: AtriCure markets its products through various brands such as Coolrail, Flex-V, and Hybrid AF, which increases the diversity of its product portfolio and enhances customer choice and market penetration.
AtriCure (ATRC) Sees a 6.32% Increase Over the Past Week: Key Information to Consider
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify promising stocks based on price trends and earnings estimate revisions.
AtriCure's Performance: AtriCure (ATRC) currently holds a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The stock has shown significant price increases, outperforming both its industry and the S&P 500 over various time frames.
Earnings Estimate Revisions: Over the past two months, AtriCure has seen positive earnings estimate revisions, with two estimates moving higher for the current year and four for the next fiscal year, indicating strong potential for future performance.
Investment Recommendations: AtriCure is highlighted as a promising stock for investors looking for momentum picks, alongside other top recommendations from Zacks Investment Research that have shown significant growth potential.
Wall Street Analysts Predict AtriCure (ATRC) May Surge 36.3%: Here's How to Invest
Stock Performance and Analyst Predictions: AtriCure (ATRC) shares have risen 3.5% recently, with Wall Street analysts projecting a mean price target of $51.44, suggesting a potential upside of 36.3%. The price targets range from $40.00 to $64.00, indicating varying levels of optimism among analysts.
Skepticism Towards Price Targets: While price targets are popular among investors, they can often mislead, as analysts may set overly optimistic targets due to business incentives. A low standard deviation in price targets indicates strong agreement among analysts, but it should not be the sole basis for investment decisions.
Earnings Estimate Revisions: Analysts have shown increased optimism regarding AtriCure's earnings, with a 32.9% rise in the Zacks Consensus Estimate for the current year. This trend in earnings estimate revisions is correlated with potential stock price movements.
Zacks Rank and Investment Outlook: AtriCure holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates. This ranking, along with a strong track record, suggests a favorable outlook for the stock despite the skepticism surrounding price targets.
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
DexCom Reports Q4 2025 Revenue of $1.26 Billion, Up 13%
- Revenue Growth: DexCom's preliminary Q4 2025 total revenue reached approximately $1.26 billion, reflecting a 13% year-over-year increase and surpassing the Zacks consensus estimate of $1.25 billion, indicating strong market performance.
- U.S. and International Performance: U.S. revenues were about $892 million, an 11% increase year-over-year, while international revenues rose 18% to around $368 million, demonstrating the effectiveness of the company's global expansion strategy.
- Gross and Operating Margins: The company estimates an adjusted gross profit margin of approximately 61% and an operating margin of 20-21% for 2025, with elevated manufacturing scrap rates impacting margins, yet operational leverage has helped achieve overall margin expansion.
- 2026 Outlook: DexCom projects total revenues for 2026 to be between $5.16 billion and $5.25 billion, representing an estimated growth of 11-13%, with expected gross margins improving to 63-64%, reflecting strong confidence in future growth and robust market demand.
VentriPoint Diagnostics Secures $1 Million Funding to Propel AI Medical Imaging Growth
- Market Growth Potential: The AI medical imaging market is projected to grow at an annual rate of 25.8% through 2034, driving a shift in healthcare from traditional hardware to agile, software-defined intelligence, creating significant opportunities for companies like VentriPoint.
- Successful Funding: VentriPoint doubled its private placement from $500,000 to $1 million, with proceeds earmarked for critical commercialization activities and manufacturing scale-up, ensuring the company maintains a competitive edge in the rapidly evolving market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby enhancing market competitiveness and driving customer adoption.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, bringing over 15 years of management experience in the medical technology sector, which is viewed as a key step in executing strategies to drive market adoption and revenue growth.
AtriCure Inc (ATRC) Releases 2025 Product Pipeline Analysis Report
- Product Pipeline Overview: AtriCure Inc's newly released 2025 Product Pipeline Analysis report provides key insights into its major products and brands, enhancing decision-making capabilities in the competitive medical technology market.
- Technical Expertise: AtriCure specializes in developing and providing medical devices for cardiac surgeries, including the Isolator Synergy ablation system and AtriClip left atrial appendage exclusion system, addressing the needs of electrophysiologists and cardiothoracic surgeons.
- Market Coverage: The company operates in multiple countries including the US, Germany, France, the UK, Canada, and Australia, showcasing its extensive global footprint aimed at enhancing competitiveness in the cardiac medical device sector.
- Brand Diversity: AtriCure markets its products through various brands such as Coolrail, Flex-V, and Hybrid AF, which increases the diversity of its product portfolio and enhances customer choice and market penetration.
AtriCure (ATRC) Sees a 6.32% Increase Over the Past Week: Key Information to Consider
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify promising stocks based on price trends and earnings estimate revisions.
AtriCure's Performance: AtriCure (ATRC) currently holds a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The stock has shown significant price increases, outperforming both its industry and the S&P 500 over various time frames.
Earnings Estimate Revisions: Over the past two months, AtriCure has seen positive earnings estimate revisions, with two estimates moving higher for the current year and four for the next fiscal year, indicating strong potential for future performance.
Investment Recommendations: AtriCure is highlighted as a promising stock for investors looking for momentum picks, alongside other top recommendations from Zacks Investment Research that have shown significant growth potential.
Wall Street Analysts Predict AtriCure (ATRC) May Surge 36.3%: Here's How to Invest
Stock Performance and Analyst Predictions: AtriCure (ATRC) shares have risen 3.5% recently, with Wall Street analysts projecting a mean price target of $51.44, suggesting a potential upside of 36.3%. The price targets range from $40.00 to $64.00, indicating varying levels of optimism among analysts.
Skepticism Towards Price Targets: While price targets are popular among investors, they can often mislead, as analysts may set overly optimistic targets due to business incentives. A low standard deviation in price targets indicates strong agreement among analysts, but it should not be the sole basis for investment decisions.
Earnings Estimate Revisions: Analysts have shown increased optimism regarding AtriCure's earnings, with a 32.9% rise in the Zacks Consensus Estimate for the current year. This trend in earnings estimate revisions is correlated with potential stock price movements.
Zacks Rank and Investment Outlook: AtriCure holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates. This ranking, along with a strong track record, suggests a favorable outlook for the stock despite the skepticism surrounding price targets.
